l-Arginine supplementation improves exercise capacity after a heart transplant  

Oleh:

Doutreleau, Stephane ; Rouyer, Olivier ; Marco, Paola Di ; Lonsdorfer, Evelyne ; Richard, Ruddy

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The American Journal of Clinical Nutrition vol. 91 no. 05 (May 2010), page 1261-1267 .
Topik: l-Arginine; heart transplant

Ketersediaan

Perpustakaan FK Nomor Panggil: A07.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Background: Endothelial dysfunction is associated with the decreased exercise capacity observed in heart-transplant (HTx) recipients. l-Arginine supplementation (LAS) stimulates the nitric oxide (NO) pathway and restores endothelial function. Objective: We compared exercise capacity in healthy subjects and HTx patients and investigated whether chronic LAS might improve exercise capacity and NO/endothelin balance after an HTx. Design: Clinical, echocardiographic, and exercise characteristics were measured in 11 control subjects and 22 HTx recipients. In a prospective, double-blind study, the 22 HTx recipients performed a 6-min exercise [6-min-walk test (6MWT)] and a maximal bicycle exercise test before and after a 6-wk period of placebo intake or LAS. Endothelial function was measured by analyzing blood NO metabolites, endothelin, and the resulting NO/endothelin balance. Results: Exercise capacity decreased after transplantation. Unlike with the placebo intake, 6 wk of LAS improved quality of life in HTx recipients (mean ± SEM Minnesota Score: from 15.3 ± 1.3 to 10.6 ± 1.1; P < 0.001) and their submaximal exercise capacity. The distance walked during the 6MWT increased (from 525 ± 20 to 580 ± 20 m; P = 0.002), and the ventilatory threshold during the incremental test was delayed by 1.2 min (P = 0.01). Central factors such as resting stroke volume, systolic pulmonary arterial pressure, cardiac systolodiastolic functions, and heart-rate reserve were not modified, but LAS significantly increased the NO:endothelin ratio (from 2.49 ± 0.38 to 3.31 ± 0.39; P = 0.03). Conclusion: Oral LAS may be a useful adjuvant therapeutic to improve quality of life and exercise tolerance in HTx recipients.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali